Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 3/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.55 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 12/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | CCND2 | P30279 | 1/20 | 0.39 |
| ▸ | CCND3 | P30281 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8268970 | 1.00 | BRPF1 (0.55) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL2614351 | 0.85 | BRPF1 (0.55) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL30066887 | 0.85 | BRPF1 (0.55) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL4292183 | 0.77 | MAPT (0.38) | MAPTCYP19A1CDC7CDK2 | |
| SCHEMBL35211518 | 0.76 | BRPF1 (0.53) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL1356214 | 0.76 | BRPF1 (0.53) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL31743104 | 0.75 | HTR6 (0.54) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL31743102 | 0.74 | HTR1D (0.54) | BRPF1CA12BRD4CA9KAT2B | |
| Pyridine SCHEMBL11505119 | 0.73 | BRPF1 (0.76) | BRPF1CA12BRD4CA9KAT2B | |
| SCHEMBL24312103 | 0.72 | HASPIN (0.44) | MAPTCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| CN-119343339-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-117580829-A | Quinoline and azaquinolines as inhibitors of CD38 | 勃林格英格翰国际有限公司 | 2024-02-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | BRPF1 2763/4885CA12 1079/4885BRD4 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.